Navigation Links
United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
Date:2/14/2013

SILVER SPRING, Md., Feb. 14, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension.  The FDA classified the resubmission as a complete, class 1 response to FDA's October 23, 2012 complete response letter and the FDA set a user fee goal date of March 31, 2013.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique medicinal products.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the FDA's user fee goal date of March 31, 2013. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 14, 2013, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United BioSource Corp. erweitert mit entscheidender Neubesetzung Potenzial in Europa
2. United BioSource Corp. expande sus capacidades europeas con contrataciones clave
3. United Kingdom Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
4. United States Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
5. Kevin Johnson Joins United Allergy Services Board Of Directors
6. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
7. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
8. Virtual Ports Receives Patent Approvals in the United States and Japan
9. United States Hospital Supplies Market Outlook to 2018 - Disposable Hospital Supplies, Mobility Aids and Transportation Equipment, Operating Room Equipment, Sterilization and Disinfectant Equipment and Others
10. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
11. Diet Doc Weight Loss Diets and Fast Weight Loss Plans To Seek Patent Protection for the Most Clinically Advanced Diet Offered in the United States.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Colombie-Britannique, February 22, 2017 Des scanners sur ... vente en Europe , au Moyen-Orient et en Afrique  ... Clarius Mobile Health , ... Vancouver , au Canada , a annoncé ... des Scanners Échographiques Sans fil Clarius C3 et L7, destinés à être ...
(Date:2/22/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, ... new research agreements and the appointment of Professor ... , MD, PhD, FRCP, as scientific advisors. The aim ... drug compounds in development for the treatment of NASH ... new collaboration with Philippe Gallay , the research ...
(Date:2/21/2017)... , Feb. 21, 2017 Mass ... report: http://www.reportlinker.com/p04711309-summary/view-report.html This report ... well as future prospects of the market globally. ... intermediaries engaged in the manufacture and commercialization of ... as new entrants planning to enter this market. ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a ... innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are used ... to accelerate tissue synthesis and provide a faster and more efficient healing process. ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The SeniorCare ... the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording ... is part of the Interactive Webinar Series. , If you want to find out ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... suffer from combat-related PTSD. , Established in 1977, our organization was at the ... of military returning to civilian life were evident and served as the catalyst ...
(Date:2/22/2017)... Wis (PRWEB) , ... February 22, 2017 , ... ... a category by itself - the Vector™ Series Multi-Cook Oven offers up to ... oven chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & ... in Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon ... clinic employees, the construction team and tribal leadership. , Choctaw Nation Durant ...
Breaking Medicine News(10 mins):